Azitra's ATR-04 rash trial pushes toward a first-cohort readout in H2 2026
The Phase 1/2 topical trial for EGFR inhibitor-associated rash is recruiting with placebo control, and its primary completion date has slipped twice, most recently by over 10 months.
Executive Summary
- Azitra is running a randomized, vehicle-controlled early-stage trial testing whether a topical live biotherapeutic can control a common and burdensome skin toxicity in cancer patients on EGFR inhibitor therapy, with first-cohort data expected in the second half of the year.
- The primary measure is safety and tolerability, not efficacy, so the readout will show whether the treatment is well tolerated before any signal on symptom improvement is a secondary consideration.
- The trial's expected completion date has been pushed back twice since the study began, extending the timeline by nearly a year, even as enrollment and trial status have progressed normally.
- No other program shares this trial's mechanism or modality in this specific dermal toxicity, leaving the readout as an isolated test of whether an engineered live biotherapeutic delivered topically can address a gap that current EGFR inhibitor rash management does not fill.
The catalyst
Azitra, Inc. expects topline data from the first cohort of its Phase 1/2 trial of topical ATR04-484 in EGFR inhibitor-associated dermal toxicity sometime between July 1 and December 31, 2026, the company said in its first-quarter 2026 update. The trial, registered as NCT06830863, is a randomized, vehicle-controlled study with one experimental arm and one placebo comparator arm, testing safety and tolerability as its primary endpoint. Three secondary endpoints track pruritus, quality of life, and severity of the dermal toxicity. The condition, caused by EGFR inhibitor cancer therapy, affects "the majority of patients receiving these therapies," Azitra chief executive Francisco Salva said in the same release. Azitra+1Azitra, Inc. Announces Q1 2026 Results and Provides Business UpdatesMay 13, 2026A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal ToxicityNCT06830863
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Site expansion
Azitra added MD Anderson Cancer Center as a clinical site for the trial in the first quarter of 2026, growing the study's footprint to enhance patient access, the company said. The trial is recruiting across six facilities in the United States and targets enrollment of 32 adults with Grade 2 or 3 non-infected EGFR inhibitor-related dermal toxicity affecting the face. Enrollment guidance has held flat at 32 patients since the trial began, a hold at target the trial's own operational model treats as routine rather than a deviation. Azitra+1Azitra, Inc. Announces Q1 2026 Results and Provides Business UpdatesMay 13, 2026A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal ToxicityNCT06830863
Timing slipped twice
The trial's primary completion date has moved twice since it launched. It shifted from February 13, 2026 to March 15, 2026 in September 2025, then from March 15, 2026 to January 15, 2027 in February 2026, a cumulative delay of roughly 11 months from the original registered date. The trial's status moved from Not yet recruiting to Recruiting in May 2025 and has not changed since. That two-step slip, alongside a site-expansion effort still underway in the same period, points to an operationally active trial working through a longer patient-accrual timeline rather than a program that has gone dark. NCT06830863A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal ToxicityNCT06830863
The competitive frame
No competing trial shares ATR-04's live biotherapeutic modality or targets EGFR inhibitor-associated dermal toxicity with a comparable mechanism; the only trial identified in this specific indication is Azitra's own. The FDA granted ATR-04 Fast Track designation for EGFR inhibitor-associated rash, a signal of unmet need in a population with no dedicated approved therapy for this toxicity. With no validated disease-modifying option in this setting and no direct mechanistic precedent, a first-cohort result that shows the topical treatment is well tolerated and moves the secondary measures of pruritus and toxicity severity in the expected direction would be the signal that supports advancing the program toward a larger trial.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.